<unk>  (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.
Volociximab
Abiciximab
Dinutuximab
Brentuximab vedotin
Bavituximab
Acalabrutinib
Blinatumomab
Pertuzumab